Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for delirium prevention in hospitalized cancer patients
NCT06834386Phase 4Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in delirium comparing Suvorexant + SoC with Standard of Care (2 arms). Primary endpoint: Recruitment Feasibility at 1 year. Planned start Feb 2025; status: withdrawn.
02
Drugs
suvorexant
03
Conditions
delirium
Beyond the preview
Go deeper on NCT06834386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834386.